Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 601–700 of 1,006
NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful
Mauro, A. G., Mezzaroma, E., Toldo, S. A., Meléndez, G. C., Franco, R. L., Lesnefsky, E. J., Abbate, A., Hundley, W. G., & Salloum, F. N. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.004 · Cited by 36
The role of platelet P2Y12 receptors in inflammation
Parker, W. A., & Storey, R. F. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16256 · Cited by 45
Cardiovascular Risk Estimation and Stratification Among Individuals with Hypercholesterolemia
Bosco, G., Mszar, R., Piro, S., Sabouret, P. F., & Gallo, A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01225-3 · Cited by 42
“In 2019, the Colchicine Cardiovascular Outcomes Trial (COLCOT) has revealed that a daily dose of 0.5 mg of colchicine resulted in a 23% reduction in the relative risk of MACE among patients who had recently experienced an ACS [69].”
InfluentialImmunothrombosis in Acute Ischemic Stroke
Wang, Y., Mulder, I. A., Westendorp, W. F., Coutinho, J. M., & van de Beek, D. (2024) · Stroke · doi:10.1161/strokeaha.124.048137 · Cited by 44
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis
Mohammadnia, N., Xue, L., Vestjens, L. T. W., Uddin, M. M., Niroula, A., de Kleijn, D. P. V., Mosterd, A., Fiolet, A. T. L., Nakao, T., Eikelboom, J. W., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.025 · Cited by 48
Acute Myocardial Infarction: Molecular Pathogenesis, Diagnosis, and Clinical Management
Zhu, M., Li, Y., Xu, Q., Wang, W., Liu, Y., & Liu, Y. (2025) · MedComm · doi:10.1002/mco2.70418 · Cited by 61
NLRP3 Inflammasome as a Common Denominator of Atherosclerosis and Abdominal Aortic Aneurysm
Takahashi, M. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0258 · Cited by 40
Karatza, E., Ismailos, G., & Karalis, V. D. (2021) · Xenobiotica · doi:10.1080/00498254.2021.1909782 · Cited by 35
“Colchicine is an alkaloid present in the plants Colchicium autumnale and Gloriosa superba, that has been used in therapeutics for its anti-inflammatory properties for ages (Putterman et al. 1991, Bhat et al. 2009, Terkeltaub 2009).”
BackgroundNew Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies
Yan, D., Blauvelt, A., Dey, A. K., Golpanian, R. S., Hwang, S. T., Mehta, N. N., Myers, B. A., Shi, Z., Yosipovitch, G., Bell, S. J., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.02.743 · Cited by 40
Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies
Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00932-5 · Cited by 35
The Emerging Role of CT-Based Imaging in Adipose Tissue and Coronary Inflammation
Yuvaraj, J., Cheng, K., Lin, A., Psaltis, P. J., Nicholls, S. J., & Wong, D. T. L. (2021) · Cells · doi:10.3390/cells10051196 · Cited by 39
The role of the mineralocorticoid receptor in immune cells in cardiovascular disease
van der Heijden, C. D. C. C., Bode, M., Riksen, N. P., & Wenzel, U. O. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15782 · Cited by 36
“A “broad-spectrum” anti-inflammatory approach using low dose colchicine in those with coronary disease in different stages also gave promising results (Tardif et al., 2019).”
BackgroundChan, Y., & Ramji, D. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_1 · Cited by 48
Interleukin-1 in Coronary Artery Disease
Oikonomou, E. K., Tsaplaris, P., Anastasiou, A., Xenou, M., Lampsas, S., Siasos, G., Pantelidis, P., Theofilis, P., Tsatsaragkou, A., Κατσαρού, Ο., et al. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221017144734 · Cited by 36
Li, Q., Huang, Z., Pang, Z., Wang, Q., Gao, J., Chen, J., Wang, Z., Tan, H., Li, S., Xu, F., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.138992 · Cited by 35
The low-dose colchicine in patients after non-CABG cardiac surgery: a randomized controlled trial
Pan, T., Jiang, C., Zhang, H., Han, X., Zhang, H.-T., Jiang, X., Chen, W., Wang, K., Fan, F.-D., Pan, J., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04341-9 · Cited by 42
Colchicine in acute myocardial infarction: cardiovascular events at 1-year follow up
Bouleti, C., Viscogliosi, S., Bresson, D., Leboube, S., Bochaton, T., Jonhy, N. E., Amaz, C., Prunier, F., Bidaux, G., Roubille, F., et al. (2024) · Open Heart · doi:10.1136/openhrt-2023-002474 · Cited by 38
Self-citationGallucci, G., Turazza, F. M., Inno, A., Canale, M. L., Silvestris, N., Farì, R., Navazio, A., Pinto, C., & Tarantini, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084232 · Cited by 41
d’Entremont, M.-A., Lee, S. F., Mian, R. I., Kedev, S., Montalescot, G., Cornel, J. H., Stankovic, G. R., Moreno, R., Storey, R. F., Henry, T. D., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.06.007 · Cited by 41
Inflammatory and Immune Mechanisms for Atherosclerotic Cardiovascular Disease in HIV
Hmiel, L., Zhang, S., Obare, L. M., Santana, M. A. D. O., Wanjalla, C. N., Titanji, B. K., Hileman, C. O., & Bagchi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137266 · Cited by 42
Cipolletta, E., Nakafero, G., McCormick, N., Yokose, C., Avery, A. J., Mamas, M. A., Choi, H. K., Tata, L. J., & Abhishek, A. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00248-0 · Cited by 45
Asare, Y., Yan, G., Schlegl, C., Prestel, M., van der Vorst, E. P. C., Teunissen, A. J. P., Aronova, A., Tosato, F., Naser, N., Caputo, J., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.003 · Cited by 42
Gao, A., Peng, B., Gao, Y., Yang, Z., Li, Z., Guo, T., Qiu, H., & Gao, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01687-8 · Cited by 43
“Recent clinical trials targeting IR among individuals with cardiovascular diseases or high cardiovascular risks have produced positive results [4–9].”
Slipczuk, L. N., Blankstein, R., Bucciarelli‐Ducci, C., Braun, L. T., Phillips, L. M., Piña, P., Shaw, L. J., Tamis‐Holland, J. E., Williamson, E. E., & Virani, S. S. (2025) · Circulation · doi:10.1161/cir.0000000000001394 · Cited by 47
Cecconi, A., Tschischke, J. P. V., Mateo, J., Sánchez‐Gonzalez, J., España, S., Fernández‐Jiménez, R., López‐Melgar, B., Fernández‐Friera, L., López-Martín, G. J., Fuster, V., et al. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09974-7 · Cited by 35
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention
Katsanos, A. H., & Hart, R. G. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2494 · Cited by 37
Mutual Interplay of Host Immune System and Gut Microbiota in the Immunopathology of Atherosclerosis
Yeh, C., Chen, Y.-H., Liu, S.-F., Kao, H., Wu, M., Yang, K., & Wu, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228729 · Cited by 40
Colchicine efficacy and safety for the treatment of cardiovascular diseases
Andreis, A., Imazio, M., Casula, M., Avondo, S., & Ferrari, G. M. D. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02654-7 · Cited by 40
“5 to 2 mg, mostly according to body weight [15, 17].”
BackgroundInflammation, atrial fibrillation, and the potential role for colchicine therapy
Varghese, B. T., Feldman, D. I., Chew, C., Valilis, E. M., Blumenthal, R. S., Sharma, G. V., & Calkins, H. G. (2021) · Heart Rhythm O2 · doi:10.1016/j.hroo.2021.03.011 · Cited by 34
Szwed, P., Gąsecka, A., Zawadka, M., Eyileten, C., Postula, M. A., Mazurek, T., Szarpak, Ł., & Filipiak, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122539 · Cited by 40
Migdalski, A., & Jawień, A. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7197 · Cited by 35
“The first reports are promising, as colchicine, in addition to high doses of statins, lowers the risk of recurrent cardiovascular episodes (70,71).”
Immune-based therapies in cardiovascular and metabolic diseases: past, present and future
Murphy, A. J., & Febbraio, M. A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00580-5 · Cited by 36
Werner, R. A., Hess, A., Koenig, T., Diekmann, J., Derlin, T., Melk, A., Thackeray, J. T., Bauersachs, J. K., & Bengel, F. M. (2021) · Theranostics · doi:10.7150/thno.61423 · Cited by 38
“Similarly, circulating inflammatory cytokines in chronic heart failure are linked with adverse outcome [7] and drugs neutralizing the inflammatory pathways effectively lower cardiovascular events among patients after myocardial infarction [8, 9].”
BackgroundFang, C., Yin, Y.-W., Jiang, S., Zhang, S., Wang, J., Wang, Y., Li, L., Wang, Y., Guo, J., Yu, H., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.07.022 · Cited by 41
Freilich, M., Arredondo, A., Zonnoor, S. L., & McFarlane, I. M. (2022) · Cureus · doi:10.7759/cureus.23582 · Cited by 47
“In conclusion, colchicine was seen to benefit this group of patients, thought to be due to its anti-inflammatory properties [34].”
BackgroundUeng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies
Andrés, M. (2023) · Gout Urate and Crystal Deposition Disease · doi:10.3390/gucdd1030014 · Cited by 36
Ayachi, S., Buscarlet, M., & Busque, L. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.008 · Cited by 33
Scicali, R., Pino, A. D., Ferrara, V., Rabuazzo, A. M., Purrello, F., & Piro, S. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01703-z · Cited by 35
C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period
Świątkiewicz, I., Magielski, P., & Kubica, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063169 · Cited by 41
“In addition, anti-inflammatory strategies including IL-1 inhibition were effective in reducing long-term risk of atherosclerotic events and HFH in post-infarct patients with low-grade inflammation [26,57,59,60].”
BackgroundFrailty is associated with chronic inflammation and pro-inflammatory monocyte subpopulations
Cybularz, M., Wydra, S., Berndt, K., Poitz, D. M., Barthel, P., Alkouri, A., Heidrich, F. M., Ibrahim, K. S., Jellinghaus, S., Speiser, U., et al. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111317 · Cited by 38
Circulatory markers of immunity and carotid atherosclerotic plaque
Fani, L., van Dam-Nolen, D. H. K., Vernooij, M. W., Kavousi, M., van der Lugt, A., & Bos, D. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.040 · Cited by 33
Different Approaches in Therapy Aiming to Stabilize an Unstable Atherosclerotic Plaque
Kowara, M., & Cudnoch‐Jędrzejewska, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094354 · Cited by 33
“7) in comparison with a placebo, which was demonstrated in the COLCOT study [129].”
ResultLiu, M., Lovern, C., Lycett, K., He, M., Wake, M. A., Wong, T. Y., & Burgner, D. P. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.025 · Cited by 43
Prevalence and real-world management of NSTEMI with multivessel disease
Baumann, A. A. W., Tavella, R., Air, T., Mishra, A., Montarello, N. J., Arstall, M. A., Zeitz, C. J., Worthley, M. I., Beltrame, J. F., & Psaltis, P. J. (2022) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-21-518 · Cited by 49
“Recent trials of colchicine are promising, though overall mortality benefit is elusive (22,23).”
BackgroundLong-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2
Opstal, T. S. J., van Broekhoven, A., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Nidorf, S. M., Thompson, P. L., Budgeon, C. A., Bartels, L., de Nooijer, R., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058233 · Cited by 33
Cardiovascular Diseases and Periodontitis
Hansen, P. R., & Holmstrup, P. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-96881-6_14 · Cited by 39
Ulcerative colitis increases risk of hypertension in a UK biobank cohort study
He, J., Zhang, S., Qiu, Y., Liu, F., Liu, Z., Tan, J., Hu, F., Wu, X., Wang, Y., Zhou, L., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12351 · Cited by 36
Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial
Opstal, T. S. J., Nidorf, S. M., Fiolet, A. T. L., Eikelboom, J. W., Mosterd, A., Bax, W. A., Budgeon, C. A., Ronner, E., Prins, F. J., Tijssen, J. G. P., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.12.026 · Cited by 33
A Potential New Link Between Inflammation and Vascular Calcification
Cai, X., Tintut, Y., & Demer, L. L. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.028358 · Cited by 40
Ngo, A. T. P., & Gollomp, K. L. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12808 · Cited by 37
C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs
Liu, C., & Li, C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad116 · Cited by 42
Younas, A., Awan, Z., Khan, T., Mehta, S., Munir, A., Raja, H. A. A., Jain, H., Raza, A., Sehar, A., Ahmed, R., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102878 · Cited by 35
Mehta, A., Blumenthal, R. S., Gluckman, T. J., Feldman, D. I., & Kohli, P. (2025) · US Cardiology Review · doi:10.15420/usc.2024.25 · Cited by 39
“45 Although the European Society of Cardiology guidelines recommend colchicine as a class 2b recommendation, they were updated prior to the CLEAR SYNERGY (OASIS 9) trial, and the use of colchicine may be lower now given the trial results.”
InfluentialMachine learning in cardiovascular risk assessment: Towards a precision medicine approach
Wang, Y., Aivalioti, E., Stamatelopoulos, K., Zervas, G., Mortensen, M. B., Zeller, M., Liberale, L., Vece, D. D., Schweiger, V., Camici, G. G., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70017 · Cited by 50
Ma, J., & Chen, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.631398 · Cited by 42
“The Efficacy and Safety of LowDose Colchicine after Myocardial Infarction [COLCOT clinical trial (28)] indicates that colchicine at a dose of 0.”
MethodSun, K., Liu, L., Hu, J., Chen, Y., & Xu, D. (2021) · Medicine · doi:10.1097/md.0000000000024579 · Cited by 44
“02).([5]) Methotrexate (MTX) is a commonly used anti-inflammatory drug that can suppress inflammation by inhibiting dihydrofolitic reductase and causing the extracellular accumulationof adenosine.”
BackgroundHoshino, M., Zhang, J., Sugiyama, T., Yang, S., Kanaji, Y., Hamaya, R., Yamaguchi, M., Hada, M., Misawa, T., Usui, E., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.03.019 · Cited by 32
Bellinge, J. W., Francis, R. J., Lee, S. C., Vickery, A. W., Macdonald, W. A., Gan, S. K., Chew, G. T., Phillips, M. R., Lewis, J. R., Watts, G. F., et al. (2021) · Journal of Nuclear Cardiology · doi:10.1007/s12350-021-02589-8 · Cited by 32
“In recent clinical trials, colchicine reduces CVD events.(12) However, the effect of colchicine on arterial calcification in humans is not known.”
BackgroundAsymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes
Stanton, A. M., Vaduganathan, M., Chang, L., Turchin, A., Januzzi, J. L., & Aroda, V. R. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01407-2 · Cited by 37
Immune modulatory effects of progesterone on oxLDL-induced trained immunity in monocytes
Groh, L. A., Verel, D. E., van der Heijden, C. D. C. C., Matzaraki, V., Moorlag, S. J. C. F. M., de Bree, L. C., Koeken, V. A. C. M., Mourits, V. P., Keating, S. T., van Puffelen, J. H., et al. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ab1220-846r · Cited by 35
Gissler, M. C., Stachon, P., Wolf, D., & Marchini, T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.826630 · Cited by 41
Ahn, J., Tantry, U. S., Kang, M. G., Park, H. W., Koh, J., Bae, J. S., Cho, S. Y., Kim, K., Jang, J. Y., Park, J. R., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2021.11.014 · Cited by 36
“02).(11) Likewise, the benefit of lowdose colchicine (0.”
BackgroundExtracellular Vesicles as Drivers of Immunoinflammation in Atherothrombosis
Suades, R., Greco, M. F., Padró, T., & Badimón, L. (2022) · Cells · doi:10.3390/cells11111845 · Cited by 35
Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction
Stähli, B. E., Klingenberg, R., Heg, D., Branca, M., Manka, R., Kapos, I., Müggler, O., Denegri, A., Kesterke, R., Berger, F., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.747 · Cited by 34
Association of endometriosis with cardiovascular disease: Genetic aspects (Review)
Vazgiourakis, V., Zervou, M. I., Papageorgiou, L., Chaniotis, D. I., Spandidos, D. A., Vlachakis, D. P., Eliopoulos, E., & Goulielmos, G. N. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5232 · Cited by 37
“The translational confirmation of this concept was provided by the Canakinumab Anti‐inflammatory Thrombosis Outcome Study (CANTOS study) (52,53) and studies using colchicine in patients with CAD (54,55).”
Repurposing Colchicine to Combat Residual Cardiovascular Risk: The LoDoCo2 Trial
Kraler, S. C., Wenzl, F. A., & Lüscher, T. F. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13424 · Cited by 33
WITHDRAWN: Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer
Batiha, G. E., Al-Gareeb, A. I., Qusti, S. Y., Alshammari, E. M., Rotimi, D., Adeyemı, O. S., & Al-Kuraishy, H. M. (2021) · Scientific African · doi:10.1016/j.sciaf.2021.e01084 · Cited by 34
“Colchicine is widely used in the management of acute gout, familial meditation fever, pericarditis, and other inflammatory disorders [64] .”
RetractedInflammation in Coronary Atherosclerosis and Its Therapeutic Implications
Montarello, N. J., Nguyen, M. T., Wong, D. T. L., Nicholls, S. J., & Psaltis, P. J. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07106-6 · Cited by 70
Emerging agents for the treatment and prevention of stroke: progress in clinical trials
Safouris, A., Magoufis, G., & Tsivgoulis, G. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985463 · Cited by 32
“5 mg daily leads to a significantly lower risk of ischemic cardiovascular events than placebo [100].”
BackgroundMargiana, R., Alsaikhan, F., Al‐Awsi, G. R. L., Patra, I., Sivaraman, R., Fadhil, A. A., Al-Baghdady, H. F. A., Qasim, M. T., Hameed, N. M., Mustafa, Y. F., et al. (2022) · Cellular Signalling · doi:10.1016/j.cellsig.2022.110471 · Cited by 63
Drug repurposing for cardiovascular diseases: New targets and indications for probenecid
Onódi, Z., Koch, S. E., Rubinstein, J., Ferdinandy, P., & Varga, Z. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.16001 · Cited by 35
Carramolino, L., Albarrán-Juárez, J., Markov, A., Hernández‐SanMiguel, E., Sharysh, D., Cumbicus, V., Morales‐Cano, D., Labrador-Cantarero, V., Møller, P. L., Nogales, P., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00412-w · Cited by 33
“ApoB lipoprotein lowering itself leads to the resolution of inflammation, but the clinical success of anti-IL-1β and colchicine indicates that the immune dampening effect is not always sufficient and that potentiating it improves standard of care 7,8 .”
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 50
“…molecules, and the activation of inflammatory cytokines, including interleukin-1 beta (IL-1 β ), tumor necrosis factor-alpha (TNF-α ), interleukin-6 (IL-6), interleukin-17 (IL-17), and interferon gamma (IFN-γ ), which were identified as potential therapeutic targets of atherosclerosis [39,41,42].”
BackgroundMechanisms Underlying Vascular Inflammaging: Current Insights and Potential Treatment Approaches
Zeng, Y., Buonfiglio, F., Li, J., Pfeiffer, N., & Gericke, A. (2025) · Aging and Disease · doi:10.14336/ad.2024.0922 · Cited by 43
“The trial demonstrated a significant reduction in the primary endpoint in the colchicine group, primarily driven by decreases in stroke and urgent revascularization events [174].”
Bacterial extracellular vesicles in the initiation, progression and treatment of atherosclerosis
Lin, Y., Wang, J., Bu, F., Zhang, R., Wang, J., Wang, Y., Huang, M., Huang, Y., Zheng, L., Wang, Q., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2452229 · Cited by 36
Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment
Arnold, N., & Köenig, W. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70020 · Cited by 36
“65 Interestingly, a 22% reduction in MACE under colchicine therapy was seen compared to placebo before the pandemic, which is in line with data from COLCOT 54 and LoDoCo2.”
InfluentialA Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure
Pepine, D., Șerban, A. M., Capraș, R.-D., Cismaru, C. M., & Filip, G. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10519-w · Cited by 49
“However, only 2% of the study population had a history of heart failure [148].”
Colchicine for the treatment of cardiovascular diseases: old drug, new targets
Andreis, A., Imazio, M., & Ferrari, G. M. D. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001079 · Cited by 35
Nanoparticle theranostics in cardiovascular inflammation
MacRitchie, N. A., Francesco, V. D., Ferreira, M. F. M. M., Guzik, T. J., Decuzzi, P., & Maffia, P. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101536 · Cited by 33
Genetzakis, E., Gilchrist, J., Kassiou, M., & Figtree, G. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108228 · Cited by 33
Yuan, D., Wang, P., Jia, S., Zhang, C., Zhu, P., Jiang, L., Liu, R., Xu, J., Tang, X., Song, Y., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.10.013 · Cited by 36
Characterization of the effect of the GLUT-1 inhibitor BAY-876 on T cells and macrophages
Chen, Z., Vaeth, M., Eckstein, M., Delgobo, M., Ramos, G. C., Frantz, S., Hofmann, U., & Gladow, N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175552 · Cited by 36
Evolving Diagnostic and Management Advances in Coronary Heart Disease
Ribeiro, M. D. O. L., Correia, V. M., de Oliveira, L. L. H., Soares, P. R., & Scudeler, T. L. (2023) · Life · doi:10.3390/life13040951 · Cited by 44
Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis
Amadori, L., Calcagno, C., Fernandez, D. M., Koplev, S., Fernandez, N., Kaur, R., Mury, P., Khan, N. S., Sajja, S., Shamailova, R., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00278-y · Cited by 33
“In 2019, the Colchicine Cardiovascular Outcomes Trial 11 showed that the antiinflammatory drug colchicine achieved similar efficacy on cardiovascular outcomes for patients with ASCVD.”
Charles‐Schoeman, C., Choy, E., McInnes, I. B., Mysler, E., Nash, P. T., Yamaoka, K., Lippe, R., Khan, N., Shmagel, A., Palac, H., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2023-003392 · Cited by 33
Short‐Term Risk of Cardiovascular Events in People Newly Diagnosed With Gout
Cipolletta, E., Nakafero, G., Richette, P., Avery, A. J., Mamas, M. A., Tata, L. J., & Abhishek, A. (2024) · Arthritis & Rheumatology · doi:10.1002/art.42986 · Cited by 34
The prevention and management of chronic kidney disease among patients with metabolic syndrome
Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025) · Kidney International · doi:10.1016/j.kint.2024.12.021 · Cited by 37
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Puri, R., Mehta, V., Duell, P. B., Nair, D. R., Mohan, J. C., Yusuf, J., Dalal, J. J., Mishra, S., Kasliwal, R. R., Agarwal, R., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.006 · Cited by 30
Neutrophil Phenotypes in Coronary Artery Disease
Maréchal, P., Tridetti, J., Nguyen, M.-L., Wéra, O., Jiang, Z., Gustin, M., Donneau, A., Oury, C., & Lancellotti, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051602 · Cited by 30
“The use of colchicine in patients with recent myocardial infarction was also effective in reducing CV events [34].”
BackgroundKADOSH, B. S., Garshick, M. S., Gaztañaga, J., Moore, K. J., Newman, J. D., Pillinger, M. H., Ramasamy, R., Reynolds, H. R., Shah, B., Hochman, J. S., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314513 · Cited by 32
Targeting epigenetics as atherosclerosis treatment: an updated view
Neele, A. E., Willemsen, L., Chen, H., Dzobo, K. E., & de Winther, M. P. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000711 · Cited by 30
“In addition, the COLCOT trial shows that in patients with a recent MI, daily treatment with the anti-inflammatory drug colchicine also significantly lowered the risk of cardiovascular events compared with its placebo arm [3].”
BackgroundTreating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Colchicine – new horizons for an ancient drug. Review based on the highest hierarchy of evidence
Schattner, A. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.002 · Cited by 33
Anti-inflammatory Strategies in Atherosclerosis
Bugger, H., & Zirlik, A. (2021) · Hämostaseologie · doi:10.1055/a-1661-0020 · Cited by 34
Macrophage Dysfunction in Autoimmune Rheumatic Diseases and Atherosclerosis
Герасимова, Е. В., Попкова, Т. В., Gerasimova, D. A., & Kirichenko, T. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094513 · Cited by 32
“CIRT [96], and COLCOT studies [97], several new anti-inflammatory and anticytokine agents are expected to be developed for the treatment of atherosclerosis [98].”
BackgroundMaierean, S. M., Webb, R. J., Banach, M., & Mazidi, M. (2022) · European Heart Journal Open · doi:10.1093/ehjopen/oeac039 · Cited by 37
Decoding microRNA drivers in atherosclerosis
Vartak, T., Kumaresan, S., & Brennan, E. P. (2022) · Bioscience Reports · doi:10.1042/bsr20212355 · Cited by 31
Ding, L., Mane, R., Wu, Z., Jiang, Y., Meng, X., Jing, J., Ou, W., Wang, X., Liu, Y., Lin, J., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101639 · Cited by 36
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

